<DOC>
	<DOCNO>NCT00843193</DOCNO>
	<brief_summary>Treatment , Randomised , Double Blind , Parallel Assignment , Safety/efficacy Study</brief_summary>
	<brief_title>Efficacy Safety Study GSK679586 Patients With Severe Asthma</brief_title>
	<detailed_description>A Multi-Centre , Multi-conutry , Randomized , Double-Blind ( Subject , Investigator ) , Placebo-Controlled , Repeat-Dose study evaluate Efficacy Safety Intravenous GSK679586 Patients Severe Asthma</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>history asthma ≥ 6 month take inhaled corticosteroid nonsmoking Baseline ( prebronchodilator ) FEV1 3580 % predict screening . Reversible airways disease indicate increase FEV1 ≥12 % baseline nebulised salbutamol albuterol . symptomatic accord ACQ7 Unstable severe asthma Recent respiratory illness Presence respiratory disease chronic pulmonary condition asthma Treatment omalizumab within 4 month study Recent gastrointestinal respiratory parasitic infestation History severe allergy food drug Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Asthma control questionnaire</keyword>
</DOC>